No biomarker
No biomarker
|
Ewing Sarcoma
Ewing Sarcoma
|
|
No biomarker
No biomarker
|
Ewing Sarcoma
Ewing Sarcoma
|
IE
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Ewing Sarcoma
Ewing Sarcoma
|
VC
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Ewing Sarcoma
Ewing Sarcoma
|
GT
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Ewing Sarcoma
Ewing Sarcoma
|
melphalan + busulfan
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Ewing Sarcoma
Ewing Sarcoma
|
ifosfamide + cyclophosphamide oral + etoposide IV + topotecan
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Ewing Sarcoma
Ewing Sarcoma
|
temozolomide + irinotecan
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Ewing Sarcoma
Ewing Sarcoma
|
temozolomide + irinotecan + vincristine
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Ewing Sarcoma
Ewing Sarcoma
|
cyclophosphamide oral + topotecan
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Ewing Sarcoma
Ewing Sarcoma
|
carboplatin + ifosfamide + etoposide IV
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Ewing Sarcoma
Ewing Sarcoma
|
gemcitabine + docetaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Ewing Sarcoma
Ewing Sarcoma
|
cabozantinib tablet
Sensitive: A2 - Guideline
|
|
Ewing Sarcoma
Ewing Sarcoma
|
pembrolizumab
Sensitive: A2 - Guideline
|
|
Ewing Sarcoma
Ewing Sarcoma
|
pembrolizumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Ewing Sarcoma
Ewing Sarcoma
|
VIDE
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Ewing Sarcoma
Ewing Sarcoma
|
VAI
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Ewing Sarcoma
Ewing Sarcoma
|
VDC
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Ewing Sarcoma
Ewing Sarcoma
|
SP2577
Sensitive: B - Late Trials
|
No biomarker
No biomarker
|
Ewing Sarcoma
Ewing Sarcoma
|
TK216
Sensitive: B - Late Trials
|
MGMT promoter methylation
MGMT promoter methylation
|
Ewing Sarcoma
Ewing Sarcoma
|
temozolomide + irinotecan
Sensitive: C2 – Inclusion Criteria
|
IGF1R underexpression
IGF1R underexpression
|
Ewing Sarcoma
Ewing Sarcoma
|
mTOR inhibitor + IGF-1R inhibitor
Sensitive: C3 – Early Trials
|
IGF1 elevation
IGF1 elevation
|
Ewing Sarcoma
Ewing Sarcoma
|
CP-751,871
Sensitive: C3 – Early Trials
|
|
Ewing Sarcoma
Ewing Sarcoma
|
mTOR inhibitor + IGF-1R inhibitor
Sensitive: C3 – Early Trials
|
PTPRD V253I + PTPRD W775stop
PTPRD V253I + PTPRD W775stop
|
Ewing Sarcoma
Ewing Sarcoma
|
mTOR inhibitor + IGF-1R inhibitor
Sensitive: C3 – Early Trials
|
PTPRD V253I + PTPRD W775stop
PTPRD V253I + PTPRD W775stop
|
Ewing Sarcoma
Ewing Sarcoma
|
IGF-1R inhibitor
Sensitive: C3 – Early Trials
|
SPARC overexpression
SPARC overexpression
|
Ewing Sarcoma
Ewing Sarcoma
|
albumin-bound paclitaxel
Sensitive: C3 – Early Trials
|
EWSR1-FLI1 fusion
EWSR1-FLI1 fusion
|
Ewing Sarcoma
Ewing Sarcoma
|
VDC
Sensitive: C4 – Case Studies
|
FGFR3 amplification + FGFR4 amplification + FLT4 amplification
FGFR3 amplification + FGFR4 amplification + FLT4 amplification
|
Ewing Sarcoma
Ewing Sarcoma
|
trametinib + pazopanib
Resistant: C4 – Case Studies
|
IGF1R expression
IGF1R expression
|
Ewing Sarcoma
Ewing Sarcoma
|
IGF-1R inhibitor
Sensitive: D – Preclinical
|
EWSR1-FLI1 fusion
EWSR1-FLI1 fusion
|
Ewing Sarcoma
Ewing Sarcoma
|
CDK12 inhibitor
Sensitive: D – Preclinical
|
FUS-ERG fusion
FUS-ERG fusion
|
Ewing Sarcoma
Ewing Sarcoma
|
ASP7487
Sensitive: D – Preclinical
|
CDKN2A deletion
CDKN2A deletion
|
Ewing Sarcoma
Ewing Sarcoma
|
ASP7487
Sensitive: D – Preclinical
|
PAK4 deletion
PAK4 deletion
|
Ewing Sarcoma
Ewing Sarcoma
|
ASP7487
Sensitive: D – Preclinical
|
FUS-ERG fusion
FUS-ERG fusion
|
Ewing Sarcoma
Ewing Sarcoma
|
palbociclib
Sensitive: D – Preclinical
|
PAK4 deletion
PAK4 deletion
|
Ewing Sarcoma
Ewing Sarcoma
|
palbociclib
Sensitive: D – Preclinical
|
CDKN2A deletion
CDKN2A deletion
|
Ewing Sarcoma
Ewing Sarcoma
|
palbociclib
Sensitive: D – Preclinical
|
CASP8 overexpression
CASP8 overexpression
|
Ewing Sarcoma
Ewing Sarcoma
|
AMG 655
Sensitive: D – Preclinical
|
